Reason: Acquired by Alfasigma
Last recorded trade on: January 10, 2024
Source: https://www.alfasigma.com/corporate/alfasigma-completes-acquisition-of-intercept-pharmaceuticals-inc/
P/E ratio for Intercept Pharmaceuticals (ICPT)
P/E ratio on January 10, 2024 (TTM): 2.97
According to Intercept Pharmaceuticals 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 2.9734. At the end of 2022 the company had a P/E ratio of 1.91.
P/E ratio history for Intercept Pharmaceuticals from 2012 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | 1.91 | -133.92% |
| 2021 | -5.64 | 91.01% |
| 2020 | -2.95 | -74.07% |
| 2019 | -11.4 | 23.63% |
| 2018 | -9.20 | 126.73% |
| 2017 | -4.06 | -37.45% |
| 2016 | -6.49 | -58.76% |
| 2015 | -15.7 | 44.56% |
| 2014 | -10.9 | -41.49% |
| 2013 | -18.6 | 182.35% |
| 2012 | -6.59 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 | 152 | 5,021.34% | 🇺🇸 USA |
 | 14.9 | 401.59% | 🇺🇸 USA |
 | 24.9 | 737.11% | 🇺🇸 USA |
 | -5.88 | -297.75% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.